Charting the Course: Strategies for Therapeutic Vaccine Study Success

Life Sciences, Clinical Trials, Pharmaceutical, Drug Discovery & Development, Fundamental Research,
  • Wednesday, October 09, 2024 | 11am EDT / 8am PDT / 4pm BST / 5pm CEST
  • 60 min

Therapeutic vaccines have emerged as a promising approach in the field of immunotherapy, with researchers striving to discover and develop a new way to treat complex diseases such as cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV).

The development of therapeutic vaccines presents distinct considerations, challenges and opportunities that differ from those encountered in the development of preventative vaccines. This webinar aims to delve into these key differences and explore the intricacies involved in the conduct of clinical trials for therapeutic vaccines.

By exploring clinical and study design considerations, reviewing the historical and current research efforts, discussing advanced modalities and defining ideal clinical trial operations and project team setups, attendees will gain valuable insights into this rapidly evolving field.

This webinar explores the current research and rationale behind the use of vaccines as therapeutics, including advanced modalities such as messenger RNA (mRNA) and cell/gene therapies. Attendees will gain a foundational understanding of the top indications and challenges faced in therapeutic vaccine development and practical considerations for conducting clinical trials.

Read more...

Emphasis will be placed on protocol and study design considerations specific to therapeutic vs. preventative vaccines. These include the identification of relevant biomarkers, the selection of appropriate adjuvants, the development of custom assays and the determination of suitable endpoints, among other aspects. The expert speakers will also examine the distinctions between early- and late-phase studies, potential endpoints and the possibility of accelerated approval.

Advanced analytical and logistical requirements will be addressed, highlighting the significance of robust processes and technologies in supporting the development and manufacturing of these innovative therapeutic vaccines. The speakers will also delve into the strategic utilization of extended and integrated services to facilitate seamless collaboration and efficient project management, effectively mitigating risks across multiple dimensions such as time, cost and patient considerations.

Read Less...

Register for this webinar today to explore advancements in therapeutic vaccine development from tackling complex diseases like cancer and HIV to the innovative use of mRNA and cell and gene therapies.

Speakers

Dr. Judith Neville, PhD, PMP, Director Project Management, Therapeutic Vaccines, PPD Clinical Research Business of Thermo Fisher Scientific

Dr. Neville is an accomplished and highly experienced Oversight Director for Therapeutic Vaccines. With a Ph.D. in Virology from the University of Edinburgh and 25 years of industry, government and academic experience, Dr. Neville possesses a deep understanding of the intricate mechanisms of viruses and their interaction with the human immune system.

Throughout her career, Dr. Neville has consistently demonstrated exceptional expertise in managing and overseeing clinical trials. Her extensive knowledge of virology, immunology, and vaccine development enables her to provide invaluable guidance in the design, implementation, and evaluation of these crucial studies.

As an Oversight Director, Judith is responsible for ensuring project delivery, from protocol design and participant recruitment to data analysis and reporting. She works closely with cross-functional teams, to ensure that all trials are conducted in accordance with industry guidelines and regulatory requirements.

With her vast experience and comprehensive understanding of clinical trial management, Dr. Neville is committed to driving innovation, fostering collaboration, and ultimately contributing to the development of safe and effective therapeutic vaccines that can revolutionize patient care and public health.

Message Presenter

Dr. Jaikrishna Balkissoon, MD, FACS Global VP, Head Cell and Gene Therapy, PPD Clinical Research Business of Thermo Fisher Scientific

Dr. Balkissoon, MD, FACS, is a Surgical Oncologist and the medical and scientific lead for immuno-oncology, cell and gene therapy at PPD. He is the visionary behind the creation of the PPD Immuno-oncology/Cell Therapy Center of Excellence. With more than 25 years’ experience in both clinical practice and clinical research, Dr. Balkissoon is committed to capitalizing on advances in the rapidly changing therapeutic landscape to establish PPD as a world-class partner in advancing immunology-oncology/cell therapy studies.

His personal immuno-oncology and cell therapy experience includes treating patients with advanced melanoma, kidney cancer and non-Hodgkin’s lymphoma with adoptive cell therapies and vaccines either with or without gene modification. He developed an immunotherapy program in Northern California for treating advanced melanoma and kidney cancer patients with high-dose interleukin-2.

At PPD, he has been the therapeutic advisor for cell therapy studies in oncology and provides drug development strategy, medical, scientific and product development guidance to both external clients and PPD’s internal clinical operations and business development teams. He also consults on investigational new drug submission and clinical input toward protocol development, including adaptive designs when feasible.

With extensive clinical oncology experience and as a Senior Executive in the pharmaceutical and biotech industries, Dr. Balkissoon joined PPD in 2013 after previously working at Genentech and Oxigene in South San Francisco where he was Vice President of Clinical Research.

Dr Balkissoon holds a Bachelor of Science in Biology from Beloit College in Wisconsin and an MD from Howard University College of Medicine in Washington, DC. He has also completed a general surgery residency at Howard University.

Message Presenter

Mario Davinelli, Executive Director, Project Management, Vaccines, PPD Clinical Research Business of Thermo Fisher Scientific

Mario Davinelli, PhD, serves as Executive Director in the Vaccines, Government and Public Health Services Therapeutic Unit at PPD Clinical Research business of Thermo Fisher Scientific. Mario leads the therapeutic vaccines business segment and the strategic proposal development services for government and public health.

Dr. Davinelli joined PPD in November 2010 and has over 20 years of global experience in clinical research, in the medical device industry and the CRO environment. He has served as Project Manager and Oversight Director in numerous clinical development multinational programs, leading large global study teams.

He has also served as a Subject Matter Expert for rare diseases and vaccines. He has therapeutic area operational experience in vaccines, infectious diseases, cardiovascular diseases, rare and genetic diseases, neuroscience, metabolic, oncology, along with extensive research operations experience in phase I-IV trials, natural history and observational studies, health authority safety surveillance studies, investigator-sponsored research (ISR), health economics and outcomes research.

Prior to joining PPD, Dr Davinelli worked for six years as a Study Manager for Medtronic. Before that he worked as a post-doc fellow at the University of Bologna, pursuing pre-clinical research in the field of biomechanics. Dr Davinelli earned his PhD in Bioengineering and Master’s degree in Electronic/Biomedical Engineering at the University of Bologna, Italy.

Message Presenter

Who Should Attend?

This webinar will appeal to:

  • Professionals in biopharma and biotech companies
  • Investigators and Site Directors of clinical research sites
  • Professionals associated with therapeutic vaccine research and development initiatives
  • Those working on therapeutic vaccine development or clinical oversight/therapeutic area interest

What You Will Learn

Attendees will learn about: 

  • Current therapeutic vaccine research focusing on cancer and infectious disease indications
  • Unique requirements and best practices in therapeutic vaccine study design and execution
  • How team composition and collaborative processes impact study success and risk mitigation strategies
  • How the challenges of therapeutic vaccine studies can be addressed

Xtalks Partner

PPD clinical research business of Thermo Fisher Scientific Inc

The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, enables customers to accelerate innovation and increase drug development productivity. Utilizing patient-centered strategies and data analytics, their capabilities cover multiple therapeutic areas and include early development, all phases of clinical development, peri- and post-approval, novel approaches to patient recruitment and investigator sites, and comprehensive laboratory services. Recognized as a global industry leader in accelerating promising medicines from early development through regulatory approval and market access, they serve pharma, biotech, medical device and government organizations with custom-tailored solutions, including full-service partnerships and functional service partnerships. As a strategic partner in clinical development and analytical services, they apply cutting edge technologies, therapeutic expertise and a firm commitment to quality to help customers deliver life-changing therapies.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account